Click for best price
Recombinant Vector Vaccines Market Size, Share 2022
Market Analysis and Insights: Global Recombinant Vector Vaccines Market
The global Recombinant Vector Vaccines market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Recombinant Vector Vaccines market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Recombinant Vector Vaccines market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Recombinant Vector Vaccines market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Recombinant Vector Vaccines market.
Global Recombinant Vector Vaccines Scope and Market Size
Recombinant Vector Vaccines market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Recombinant Vector Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Varicella
Influenza
Polio
Hepatitis A
Rabies
BCG
Hepatitis B
Pertussis, Diphtheria, tetanus
Pneumococcal
Others
Segment by Application
For Adult
For Child
By Company
SANOFI PASTEUR S.A.
Novartis
GSK
CNBG
ChengDa Bio
Changsheng Life
Zhifei
SINOVAC BIOTECH
NuoCheng Bio
Hualan Bio
Kangtai
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The information for each competitor/Company Profile includes:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The content of the study subjects includes a total of 15 chapters:
Chapter 1, describes Recombinant Vector Vaccines product scope, market overview, market opportunities, market driving force, and market risks.
Chapter 2, profiles the top manufacturers of Recombinant Vector Vaccines, with price, sales, revenue, and global market share of Recombinant Vector Vaccines from 2019 to 2022.
Chapter 3, the Recombinant Vector Vaccines competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Recombinant Vector Vaccines breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.
Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Recombinant Vector Vaccines market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Recombinant Vector Vaccines.
Chapter 13, 14, and 15, to describe Recombinant Vector Vaccines sales channel, distributors, customers, research findings and conclusion, appendix and data source.
Key Indicators Analysed:
- Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
- Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
- Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
- Opportunities and Drivers: Identifying the Growing Demands and New Technology
- Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.
Reasons to Purchase this Report:
- Estimates 2022-2027 2021-2025 Recombinant Vector Vaccines Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
- Market dynamics scenario, along with growth opportunities of the market in the years to come
- Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
- Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
- Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
- Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
- Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
- 1-year analyst support, along with the data support in excel format.
Research Methodology:
The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
| Report Attributes |
Report Details |
| Report Title |
Global Recombinant Vector Vaccines Market Insights, Forecast to 2028 |
| Historical Year |
2018 to 2022 (Data from 2010 can be provided as per availability) |
| Base Year |
2021 |
| Forecast Year |
2029 |
| Number of Pages |
106 Pages |
| Customization Available |
Yes, the report can be customized as per your need. |
TABLE OF CONTENTS
1 Study Coverage
1.1 Recombinant Vector Vaccines Product Introduction
1.2 Market by Type
1.2.1 Global Recombinant Vector Vaccines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Varicella
1.2.3 Influenza
1.2.4 Polio
1.2.5 Hepatitis A
1.2.6 Rabies
1.2.7 BCG
1.2.8 Hepatitis B
1.2.9 Pertussis, Diphtheria, tetanus
1.2.10 Pneumococcal
1.2.11 Others
1.3 Market by Application
1.3.1 Global Recombinant Vector Vaccines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 For Adult
1.3.3 For Child
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Recombinant Vector Vaccines Sales Estimates and Forecasts 2017-2028
2.2 Global Recombinant Vector Vaccines Revenue Estimates and Forecasts 2017-2028
2.3 Global Recombinant Vector Vaccines Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Recombinant Vector Vaccines Sales by Region
2.4.1 Global Recombinant Vector Vaccines Sales by Region (2017-2022)
2.4.2 Global Sales Recombinant Vector Vaccines by Region (2023-2028)
2.5 Global Recombinant Vector Vaccines Revenue by Region
2.5.1 Global Recombinant Vector Vaccines Revenue by Region (2017-2022)
2.5.2 Global Recombinant Vector Vaccines Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Recombinant Vector Vaccines Sales by Manufacturers
3.1.1 Global Top Recombinant Vector Vaccines Manufacturers by Sales (2017-2022)
3.1.2 Global Recombinant Vector Vaccines Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant Vector Vaccines in 2021
3.2 Global Recombinant Vector Vaccines Revenue by Manufacturers
3.2.1 Global Recombinant Vector Vaccines Revenue by Manufacturers (2017-2022)
3.2.2 Global Recombinant Vector Vaccines Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Recombinant Vector Vaccines Revenue in 2021
3.3 Global Recombinant Vector Vaccines Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Recombinant Vector Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Recombinant Vector Vaccines Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Recombinant Vector Vaccines Sales by Type
4.1.1 Global Recombinant Vector Vaccines Historical Sales by Type (2017-2022)
4.1.2 Global Recombinant Vector Vaccines Forecasted Sales by Type (2023-2028)
4.1.3 Global Recombinant Vector Vaccines Sales Market Share by Type (2017-2028)
4.2 Global Recombinant Vector Vaccines Revenue by Type
4.2.1 Global Recombinant Vector Vaccines Historical Revenue by Type (2017-2022)
4.2.2 Global Recombinant Vector Vaccines Forecasted Revenue by Type (2023-2028)
4.2.3 Global Recombinant Vector Vaccines Revenue Market Share by Type (2017-2028)
4.3 Global Recombinant Vector Vaccines Price by Type
4.3.1 Global Recombinant Vector Vaccines Price by Type (2017-2022)
4.3.2 Global Recombinant Vector Vaccines Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Recombinant Vector Vaccines Sales by Application
5.1.1 Global Recombinant Vector Vaccines Historical Sales by Application (2017-2022)
5.1.2 Global Recombinant Vector Vaccines Forecasted Sales by Application (2023-2028)
5.1.3 Global Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
5.2 Global Recombinant Vector Vaccines Revenue by Application
5.2.1 Global Recombinant Vector Vaccines Historical Revenue by Application (2017-2022)
5.2.2 Global Recombinant Vector Vaccines Forecasted Revenue by Application (2023-2028)
5.2.3 Global Recombinant Vector Vaccines Revenue Market Share by Application (2017-2028)
5.3 Global Recombinant Vector Vaccines Price by Application
5.3.1 Global Recombinant Vector Vaccines Price by Application (2017-2022)
5.3.2 Global Recombinant Vector Vaccines Price Forecast by Application (2023-2028)
6 North America
6.1 North America Recombinant Vector Vaccines Market Size by Type
6.1.1 North America Recombinant Vector Vaccines Sales by Type (2017-2028)
6.1.2 North America Recombinant Vector Vaccines Revenue by Type (2017-2028)
6.2 North America Recombinant Vector Vaccines Market Size by Application
6.2.1 North America Recombinant Vector Vaccines Sales by Application (2017-2028)
6.2.2 North America Recombinant Vector Vaccines Revenue by Application (2017-2028)
6.3 North America Recombinant Vector Vaccines Market Size by Country
6.3.1 North America Recombinant Vector Vaccines Sales by Country (2017-2028)
6.3.2 North America Recombinant Vector Vaccines Revenue by Country (2017-2028)
6.3.3 U.S.
6.3.4 Canada
7 Europe
7.1 Europe Recombinant Vector Vaccines Market Size by Type
7.1.1 Europe Recombinant Vector Vaccines Sales by Type (2017-2028)
7.1.2 Europe Recombinant Vector Vaccines Revenue by Type (2017-2028)
7.2 Europe Recombinant Vector Vaccines Market Size by Application
7.2.1 Europe Recombinant Vector Vaccines Sales by Application (2017-2028)
7.2.2 Europe Recombinant Vector Vaccines Revenue by Application (2017-2028)
7.3 Europe Recombinant Vector Vaccines Market Size by Country
7.3.1 Europe Recombinant Vector Vaccines Sales by Country (2017-2028)
7.3.2 Europe Recombinant Vector Vaccines Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Recombinant Vector Vaccines Market Size by Type
8.1.1 Asia Pacific Recombinant Vector Vaccines Sales by Type (2017-2028)
8.1.2 Asia Pacific Recombinant Vector Vaccines Revenue by Type (2017-2028)
8.2 Asia Pacific Recombinant Vector Vaccines Market Size by Application
8.2.1 Asia Pacific Recombinant Vector Vaccines Sales by Application (2017-2028)
8.2.2 Asia Pacific Recombinant Vector Vaccines Revenue by Application (2017-2028)
8.3 Asia Pacific Recombinant Vector Vaccines Market Size by Region
8.3.1 Asia Pacific Recombinant Vector Vaccines Sales by Region (2017-2028)
8.3.2 Asia Pacific Recombinant Vector Vaccines Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
8.3.12 Philippines
9 Latin America
9.1 Latin America Recombinant Vector Vaccines Market Size by Type
9.1.1 Latin America Recombinant Vector Vaccines Sales by Type (2017-2028)
9.1.2 Latin America Recombinant Vector Vaccines Revenue by Type (2017-2028)
9.2 Latin America Recombinant Vector Vaccines Market Size by Application
9.2.1 Latin America Recombinant Vector Vaccines Sales by Application (2017-2028)
9.2.2 Latin America Recombinant Vector Vaccines Revenue by Application (2017-2028)
9.3 Latin America Recombinant Vector Vaccines Market Size by Country
9.3.1 Latin America Recombinant Vector Vaccines Sales by Country (2017-2028)
9.3.2 Latin America Recombinant Vector Vaccines Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Recombinant Vector Vaccines Market Size by Type
10.1.1 Middle East and Africa Recombinant Vector Vaccines Sales by Type (2017-2028)
10.1.2 Middle East and Africa Recombinant Vector Vaccines Revenue by Type (2017-2028)
10.2 Middle East and Africa Recombinant Vector Vaccines Market Size by Application
10.2.1 Middle East and Africa Recombinant Vector Vaccines Sales by Application (2017-2028)
10.2.2 Middle East and Africa Recombinant Vector Vaccines Revenue by Application (2017-2028)
10.3 Middle East and Africa Recombinant Vector Vaccines Market Size by Country
10.3.1 Middle East and Africa Recombinant Vector Vaccines Sales by Country (2017-2028)
10.3.2 Middle East and Africa Recombinant Vector Vaccines Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 SANOFI PASTEUR S.A.
11.1.1 SANOFI PASTEUR S.A. Corporation Information
11.1.2 SANOFI PASTEUR S.A. Overview
11.1.3 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 SANOFI PASTEUR S.A. Recent Developments
11.2 Novartis
11.2.1 Novartis Corporation Information
11.2.2 Novartis Overview
11.2.3 Novartis Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Novartis Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Novartis Recent Developments
11.3 GSK
11.3.1 GSK Corporation Information
11.3.2 GSK Overview
11.3.3 GSK Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 GSK Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 GSK Recent Developments
11.4 CNBG
11.4.1 CNBG Corporation Information
11.4.2 CNBG Overview
11.4.3 CNBG Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 CNBG Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 CNBG Recent Developments
11.5 ChengDa Bio
11.5.1 ChengDa Bio Corporation Information
11.5.2 ChengDa Bio Overview
11.5.3 ChengDa Bio Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 ChengDa Bio Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 ChengDa Bio Recent Developments
11.6 Changsheng Life
11.6.1 Changsheng Life Corporation Information
11.6.2 Changsheng Life Overview
11.6.3 Changsheng Life Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Changsheng Life Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Changsheng Life Recent Developments
11.7 Zhifei
11.7.1 Zhifei Corporation Information
11.7.2 Zhifei Overview
11.7.3 Zhifei Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Zhifei Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Zhifei Recent Developments
11.8 SINOVAC BIOTECH
11.8.1 SINOVAC BIOTECH Corporation Information
11.8.2 SINOVAC BIOTECH Overview
11.8.3 SINOVAC BIOTECH Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 SINOVAC BIOTECH Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 SINOVAC BIOTECH Recent Developments
11.9 NuoCheng Bio
11.9.1 NuoCheng Bio Corporation Information
11.9.2 NuoCheng Bio Overview
11.9.3 NuoCheng Bio Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 NuoCheng Bio Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 NuoCheng Bio Recent Developments
11.10 Hualan Bio
11.10.1 Hualan Bio Corporation Information
11.10.2 Hualan Bio Overview
11.10.3 Hualan Bio Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Hualan Bio Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Hualan Bio Recent Developments
11.11 Kangtai
11.11.1 Kangtai Corporation Information
11.11.2 Kangtai Overview
11.11.3 Kangtai Recombinant Vector Vaccines Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Kangtai Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Kangtai Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Recombinant Vector Vaccines Industry Chain Analysis
12.2 Recombinant Vector Vaccines Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Recombinant Vector Vaccines Production Mode & Process
12.4 Recombinant Vector Vaccines Sales and Marketing
12.4.1 Recombinant Vector Vaccines Sales Channels
12.4.2 Recombinant Vector Vaccines Distributors
12.5 Recombinant Vector Vaccines Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Recombinant Vector Vaccines Industry Trends
13.2 Recombinant Vector Vaccines Market Drivers
13.3 Recombinant Vector Vaccines Market Challenges
13.4 Recombinant Vector Vaccines Market Restraints
14 Key Findings in The Global Recombinant Vector Vaccines Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer
LIST OF TABLES & FIGURES
List of Tables
Table 1. Global Recombinant Vector Vaccines Market Size Growth Rate by Type, 2017 VS 2021 VS 2028 (US$ Million)
Table 2. Major Manufacturers of Varicella
Table 3. Major Manufacturers of Influenza
Table 4. Major Manufacturers of Polio
Table 5. Major Manufacturers of Hepatitis A
Table 6. Major Manufacturers of Rabies
Table 7. Major Manufacturers of BCG
Table 8. Major Manufacturers of Hepatitis B
Table 9. Major Manufacturers of Pertussis, Diphtheria, tetanus
Table 10. Major Manufacturers of Pneumococcal
Table 11. Major Manufacturers of Others
Table 12. Global Recombinant Vector Vaccines Market Size Growth Rate by Application, 2017 VS 2021 VS 2028 (US$ Million)
Table 13. Global Recombinant Vector Vaccines Revenue by Region: 2017 VS 2021 VS 2028 (US$ Million)
Table 14. Global Recombinant Vector Vaccines Sales by Region (2017-2022) & (K Doses)
Table 15. Global Recombinant Vector Vaccines Sales Market Share by Region (2017-2022)
Table 16. Global Recombinant Vector Vaccines Sales by Region (2023-2028) & (K Doses)
Table 17. Global Recombinant Vector Vaccines Sales Market Share by Region (2023-2028)
Table 18. Global Recombinant Vector Vaccines Revenue by Region (2017-2022) & (US$ Million)
Table 19. Global Recombinant Vector Vaccines Revenue Market Share by Region (2017-2022)
Table 20. Global Recombinant Vector Vaccines Revenue by Region (2023-2028) & (US$ Million)
Table 21. Global Recombinant Vector Vaccines Revenue Market Share by Region (2023-2028)
Table 22. Global Recombinant Vector Vaccines Sales by Manufacturers (2017-2022) & (K Doses)
Table 23. Global Recombinant Vector Vaccines Sales Share by Manufacturers (2017-2022)
Table 24. Global Recombinant Vector Vaccines Revenue by Manufacturers (2017-2022) & (US$ Million)
Table 25. Global Recombinant Vector Vaccines Revenue Share by Manufacturers (2017-2022)
Table 26. Recombinant Vector Vaccines Price by Manufacturers (2017-2022) &(USD/Dose)
Table 27. Global Recombinant Vector Vaccines Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 28. Global Recombinant Vector Vaccines by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Vector Vaccines as of 2021)
Table 29. Recombinant Vector Vaccines Manufacturing Base Distribution and Headquarters
Table 30. Manufacturers Recombinant Vector Vaccines Product Offered
Table 31. Date of Manufacturers Enter into Recombinant Vector Vaccines Market
Table 32. Mergers & Acquisitions, Expansion Plans
Table 33. Global Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 34. Global Recombinant Vector Vaccines Sales by Type (2023-2028) & (K Doses)
Table 35. Global Recombinant Vector Vaccines Sales Share by Type (2017-2022)
Table 36. Global Recombinant Vector Vaccines Sales Share by Type (2023-2028)
Table 37. Global Recombinant Vector Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 38. Global Recombinant Vector Vaccines Revenue by Type (2023-2028) & (US$ Million)
Table 39. Global Recombinant Vector Vaccines Revenue Share by Type (2017-2022)
Table 40. Global Recombinant Vector Vaccines Revenue Share by Type (2023-2028)
Table 41. Recombinant Vector Vaccines Price by Type (2017-2022) & (USD/Dose)
Table 42. Global Recombinant Vector Vaccines Price Forecast by Type (2023-2028) & (USD/Dose)
Table 43. Global Recombinant Vector Vaccines Sales by Application (2017-2022) & (K Doses)
Table 44. Global Recombinant Vector Vaccines Sales by Application (2023-2028) & (K Doses)
Table 45. Global Recombinant Vector Vaccines Sales Share by Application (2017-2022)
Table 46. Global Recombinant Vector Vaccines Sales Share by Application (2023-2028)
Table 47. Global Recombinant Vector Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 48. Global Recombinant Vector Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 49. Global Recombinant Vector Vaccines Revenue Share by Application (2017-2022)
Table 50. Global Recombinant Vector Vaccines Revenue Share by Application (2023-2028)
Table 51. Recombinant Vector Vaccines Price by Application (2017-2022) & (USD/Dose)
Table 52. Global Recombinant Vector Vaccines Price Forecast by Application (2023-2028) & (USD/Dose)
Table 53. North America Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 54. North America Recombinant Vector Vaccines Sales by Type (2023-2028) & (K Doses)
Table 55. North America Recombinant Vector Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 56. North America Recombinant Vector Vaccines Revenue by Type (2023-2028) & (US$ Million)
Table 57. North America Recombinant Vector Vaccines Sales by Application (2017-2022) & (K Doses)
Table 58. North America Recombinant Vector Vaccines Sales by Application (2023-2028) & (K Doses)
Table 59. North America Recombinant Vector Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 60. North America Recombinant Vector Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 61. North America Recombinant Vector Vaccines Sales by Country (2017-2022) & (K Doses)
Table 62. North America Recombinant Vector Vaccines Sales by Country (2023-2028) & (K Doses)
Table 63. North America Recombinant Vector Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 64. North America Recombinant Vector Vaccines Revenue by Country (2023-2028) & (US$ Million)
Table 65. Europe Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 66. Europe Recombinant Vector Vaccines Sales by Type (2023-2028) & (K Doses)
Table 67. Europe Recombinant Vector Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 68. Europe Recombinant Vector Vaccines Revenue by Type (2023-2028) & (US$ Million)
Table 69. Europe Recombinant Vector Vaccines Sales by Application (2017-2022) & (K Doses)
Table 70. Europe Recombinant Vector Vaccines Sales by Application (2023-2028) & (K Doses)
Table 71. Europe Recombinant Vector Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 72. Europe Recombinant Vector Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 73. Europe Recombinant Vector Vaccines Sales by Country (2017-2022) & (K Doses)
Table 74. Europe Recombinant Vector Vaccines Sales by Country (2023-2028) & (K Doses)
Table 75. Europe Recombinant Vector Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 76. Europe Recombinant Vector Vaccines Revenue by Country (2023-2028) & (US$ Million)
Table 77. Asia Pacific Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 78. Asia Pacific Recombinant Vector Vaccines Sales by Type (2023-2028) & (K Doses)
Table 79. Asia Pacific Recombinant Vector Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 80. Asia Pacific Recombinant Vector Vaccines Revenue by Type (2023-2028) & (US$ Million)
Table 81. Asia Pacific Recombinant Vector Vaccines Sales by Application (2017-2022) & (K Doses)
Table 82. Asia Pacific Recombinant Vector Vaccines Sales by Application (2023-2028) & (K Doses)
Table 83. Asia Pacific Recombinant Vector Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 84. Asia Pacific Recombinant Vector Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 85. Asia Pacific Recombinant Vector Vaccines Sales by Region (2017-2022) & (K Doses)
Table 86. Asia Pacific Recombinant Vector Vaccines Sales by Region (2023-2028) & (K Doses)
Table 87. Asia Pacific Recombinant Vector Vaccines Revenue by Region (2017-2022) & (US$ Million)
Table 88. Asia Pacific Recombinant Vector Vaccines Revenue by Region (2023-2028) & (US$ Million)
Table 89. Latin America Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 90. Latin America Recombinant Vector Vaccines Sales by Type (2023-2028) & (K Doses)
Table 91. Latin America Recombinant Vector Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 92. Latin America Recombinant Vector Vaccines Revenue by Type (2023-2028) & (US$ Million)
Table 93. Latin America Recombinant Vector Vaccines Sales by Application (2017-2022) & (K Doses)
Table 94. Latin America Recombinant Vector Vaccines Sales by Application (2023-2028) & (K Doses)
Table 95. Latin America Recombinant Vector Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 96. Latin America Recombinant Vector Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 97. Latin America Recombinant Vector Vaccines Sales by Country (2017-2022) & (K Doses)
Table 98. Latin America Recombinant Vector Vaccines Sales by Country (2023-2028) & (K Doses)
Table 99. Latin America Recombinant Vector Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 100. Latin America Recombinant Vector Vaccines Revenue by Country (2023-2028) & (US$ Million)
Table 101. Middle East and Africa Recombinant Vector Vaccines Sales by Type (2017-2022) & (K Doses)
Table 102. Middle East and Africa Recombinant Vector Vaccines Sales by Type (2023-2028) & (K Doses)
Table 103. Middle East and Africa Recombinant Vector Vaccines Revenue by Type (2017-2022) & (US$ Million)
Table 104. Middle East and Africa Recombinant Vector Vaccines Revenue by Type (2023-2028) & (US$ Million)
Table 105. Middle East and Africa Recombinant Vector Vaccines Sales by Application (2017-2022) & (K Doses)
Table 106. Middle East and Africa Recombinant Vector Vaccines Sales by Application (2023-2028) & (K Doses)
Table 107. Middle East and Africa Recombinant Vector Vaccines Revenue by Application (2017-2022) & (US$ Million)
Table 108. Middle East and Africa Recombinant Vector Vaccines Revenue by Application (2023-2028) & (US$ Million)
Table 109. Middle East and Africa Recombinant Vector Vaccines Sales by Country (2017-2022) & (K Doses)
Table 110. Middle East and Africa Recombinant Vector Vaccines Sales by Country (2023-2028) & (K Doses)
Table 111. Middle East and Africa Recombinant Vector Vaccines Revenue by Country (2017-2022) & (US$ Million)
Table 112. Middle East and Africa Recombinant Vector Vaccines Revenue by Country (2023-2028) & (US$ Million)
Table 113. SANOFI PASTEUR S.A. Corporation Information
Table 114. SANOFI PASTEUR S.A. Description and Major Businesses
Table 115. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 116. SANOFI PASTEUR S.A. Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 117. SANOFI PASTEUR S.A. Recent Developments
Table 118. Novartis Corporation Information
Table 119. Novartis Description and Major Businesses
Table 120. Novartis Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 121. Novartis Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 122. Novartis Recent Developments
Table 123. GSK Corporation Information
Table 124. GSK Description and Major Businesses
Table 125. GSK Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 126. GSK Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 127. GSK Recent Developments
Table 128. CNBG Corporation Information
Table 129. CNBG Description and Major Businesses
Table 130. CNBG Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 131. CNBG Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 132. CNBG Recent Developments
Table 133. ChengDa Bio Corporation Information
Table 134. ChengDa Bio Description and Major Businesses
Table 135. ChengDa Bio Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 136. ChengDa Bio Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 137. ChengDa Bio Recent Developments
Table 138. Changsheng Life Corporation Information
Table 139. Changsheng Life Description and Major Businesses
Table 140. Changsheng Life Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 141. Changsheng Life Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 142. Changsheng Life Recent Developments
Table 143. Zhifei Corporation Information
Table 144. Zhifei Description and Major Businesses
Table 145. Zhifei Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 146. Zhifei Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 147. Zhifei Recent Developments
Table 148. SINOVAC BIOTECH Corporation Information
Table 149. SINOVAC BIOTECH Description and Major Businesses
Table 150. SINOVAC BIOTECH Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 151. SINOVAC BIOTECH Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 152. SINOVAC BIOTECH Recent Developments
Table 153. NuoCheng Bio Corporation Information
Table 154. NuoCheng Bio Description and Major Businesses
Table 155. NuoCheng Bio Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 156. NuoCheng Bio Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 157. NuoCheng Bio Recent Developments
Table 158. Hualan Bio Corporation Information
Table 159. Hualan Bio Description and Major Businesses
Table 160. Hualan Bio Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 161. Hualan Bio Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 162. Hualan Bio Recent Developments
Table 163. Kangtai Corporation Information
Table 164. Kangtai Description and Major Businesses
Table 165. Kangtai Recombinant Vector Vaccines Sales (K Doses), Revenue (US$ Million), Price (USD/Dose) and Gross Margin (2017-2022)
Table 166. Kangtai Recombinant Vector Vaccines Product Model Numbers, Pictures, Descriptions and Specifications
Table 167. Kangtai Recent Developments
Table 168. Key Raw Materials Lists
Table 169. Raw Materials Key Suppliers Lists
Table 170. Recombinant Vector Vaccines Distributors List
Table 171. Recombinant Vector Vaccines Customers List
Table 172. Recombinant Vector Vaccines Market Trends
Table 173. Recombinant Vector Vaccines Market Drivers
Table 174. Recombinant Vector Vaccines Market Challenges
Table 175. Recombinant Vector Vaccines Market Restraints
Table 176. Research Programs/Design for This Report
Table 177. Key Data Information from Secondary Sources
Table 178. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Vector Vaccines Product Picture
Figure 3. Global Recombinant Vector Vaccines Market Share by Type in 2021 & 2028
Figure 3. Varicella Product Picture
Figure 4. Influenza Product Picture
Figure 5. Polio Product Picture
Figure 6. Hepatitis A Product Picture
Figure 7. Rabies Product Picture
Figure 8. BCG Product Picture
Figure 9. Hepatitis B Product Picture
Figure 10. Pertussis, Diphtheria, tetanus Product Picture
Figure 11. Pneumococcal Product Picture
Figure 12. Others Product Picture
Figure 13. Global Recombinant Vector Vaccines Market Share by Application in 2021 & 2028
Figure 14. For Adult
Figure 15. For Child
Figure 16. Recombinant Vector Vaccines Report Years Considered
Figure 17. Global Recombinant Vector Vaccines Sales 2017-2028 (K Doses)
Figure 18. Global Recombinant Vector Vaccines Revenue, (US$ Million), 2017 VS 2021 VS 2028
Figure 19. Global Recombinant Vector Vaccines Revenue 2017-2028 (US$ Million)
Figure 20. Global Recombinant Vector Vaccines Revenue Market Share by Region in Percentage: 2021 Versus 2028
Figure 21. Global Recombinant Vector Vaccines Sales Market Share by Region (2017-2022)
Figure 22. Global Recombinant Vector Vaccines Sales Market Share by Region (2023-2028)
Figure 23. North America Recombinant Vector Vaccines Sales YoY (2017-2028) & (K Doses)
Figure 24. North America Recombinant Vector Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 25. Europe Recombinant Vector Vaccines Sales YoY (2017-2028) & (K Doses)
Figure 26. Europe Recombinant Vector Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 27. Asia-Pacific Recombinant Vector Vaccines Sales YoY (2017-2028) & (K Doses)
Figure 28. Asia-Pacific Recombinant Vector Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 29. Latin America Recombinant Vector Vaccines Sales YoY (2017-2028) & (K Doses)
Figure 30. Latin America Recombinant Vector Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 31. Middle East & Africa Recombinant Vector Vaccines Sales YoY (2017-2028) & (K Doses)
Figure 32. Middle East & Africa Recombinant Vector Vaccines Revenue YoY (2017-2028) & (US$ Million)
Figure 33. The Recombinant Vector Vaccines Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2021
Figure 34. The Top 5 and 10 Largest Manufacturers of Recombinant Vector Vaccines in the World: Market Share by Recombinant Vector Vaccines Revenue in 2021
Figure 35. Global Recombinant Vector Vaccines Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2017 VS 2021
Figure 36. Global Recombinant Vector Vaccines Sales Market Share by Type (2017-2028)
Figure 37. Global Recombinant Vector Vaccines Revenue Market Share by Type (2017-2028)
Figure 38. Global Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
Figure 39. Global Recombinant Vector Vaccines Revenue Market Share by Application (2017-2028)
Figure 40. North America Recombinant Vector Vaccines Sales Market Share by Type (2017-2028)
Figure 41. North America Recombinant Vector Vaccines Revenue Market Share by Type (2017-2028)
Figure 42. North America Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
Figure 43. North America Recombinant Vector Vaccines Revenue Market Share by Application (2017-2028)
Figure 44. North America Recombinant Vector Vaccines Sales Share by Country (2017-2028)
Figure 45. North America Recombinant Vector Vaccines Revenue Share by Country (2017-2028)
Figure 46. U.S. Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 47. Canada Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 48. Europe Recombinant Vector Vaccines Sales Market Share by Type (2017-2028)
Figure 49. Europe Recombinant Vector Vaccines Revenue Market Share by Type (2017-2028)
Figure 50. Europe Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
Figure 51. Europe Recombinant Vector Vaccines Revenue Market Share by Application (2017-2028)
Figure 52. Europe Recombinant Vector Vaccines Sales Share by Country (2017-2028)
Figure 53. Europe Recombinant Vector Vaccines Revenue Share by Country (2017-2028)
Figure 54. Germany Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 55. France Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 56. U.K. Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 57. Italy Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 58. Russia Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 59. Asia Pacific Recombinant Vector Vaccines Sales Market Share by Type (2017-2028)
Figure 60. Asia Pacific Recombinant Vector Vaccines Revenue Market Share by Type (2017-2028)
Figure 61. Asia Pacific Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
Figure 62. Asia Pacific Recombinant Vector Vaccines Revenue Market Share by Application (2017-2028)
Figure 63. Asia Pacific Recombinant Vector Vaccines Sales Share by Region (2017-2028)
Figure 64. Asia Pacific Recombinant Vector Vaccines Revenue Share by Region (2017-2028)
Figure 65. China Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 66. Japan Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 67. South Korea Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 68. India Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 69. Australia Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 70. Taiwan Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 71. Indonesia Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 72. Thailand Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 73. Malaysia Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 74. Philippines Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 75. Latin America Recombinant Vector Vaccines Sales Market Share by Type (2017-2028)
Figure 76. Latin America Recombinant Vector Vaccines Revenue Market Share by Type (2017-2028)
Figure 77. Latin America Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
Figure 78. Latin America Recombinant Vector Vaccines Revenue Market Share by Application (2017-2028)
Figure 79. Latin America Recombinant Vector Vaccines Sales Share by Country (2017-2028)
Figure 80. Latin America Recombinant Vector Vaccines Revenue Share by Country (2017-2028)
Figure 81. Mexico Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 82. Brazil Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 83. Argentina Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 84. Middle East and Africa Recombinant Vector Vaccines Sales Market Share by Type (2017-2028)
Figure 85. Middle East and Africa Recombinant Vector Vaccines Revenue Market Share by Type (2017-2028)
Figure 86. Middle East and Africa Recombinant Vector Vaccines Sales Market Share by Application (2017-2028)
Figure 87. Middle East and Africa Recombinant Vector Vaccines Revenue Market Share by Application (2017-2028)
Figure 88. Middle East and Africa Recombinant Vector Vaccines Sales Share by Country (2017-2028)
Figure 89. Middle East and Africa Recombinant Vector Vaccines Revenue Share by Country (2017-2028)
Figure 90. Turkey Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 91. Saudi Arabia Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 92. U.A.E Recombinant Vector Vaccines Revenue (2017-2028) & (US$ Million)
Figure 93. Recombinant Vector Vaccines Value Chain
Figure 94. Recombinant Vector Vaccines Production Process
Figure 95. Channels of Distribution
Figure 96. Distributors Profiles
Figure 97. Bottom-up and Top-down Approaches for This Report
Figure 98. Data Triangulation
Figure 99. Key Executives Interviewed
